Skip to content

Hydroxytyrosol Caramel Treatment on Cardiovascular Risk Patients

Assessing the Impact of Hydroxytyrosol Caramel Treatment on the Cardiometabolic Health of Patients at Cardiovascular Risk Disease

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06319417
Enrollment
26
Registered
2024-03-20
Start date
2022-04-15
Completion date
2023-03-23
Last updated
2024-03-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiovascular Pathology

Keywords

hydroxytyrosol, cardiovascular risk, crossover, randomized

Brief summary

The goal of this double-blind crossover randomized clinical trial is to evaluate the impact of a phenolic natural compound called hydroxytyrosol (HT) on patients at cardiovascular risk (CVR). The main questions it aims to answer are: * Evaluating the effect of HT caramels on CVR biomarkers. * Assessing the impact of HT caramels on cellular phenotype. Participants will take 4 caramels/day, each containing 15 mg of HT, consuming a daily intake of 60 mg for 28 days. One group will begin with HT caramel consumption for 28 days, while the other group will start with a placebo treatment. Following a 2-week washout period, the treatments will be switched between the groups. Those who initially consumed HT will then switch to the placebo treatment, and vice-versa, each for a duration of 28 days.

Detailed description

A 10-week randomized, crossover, double-blind controlled clinical trial was conducted between April 2022 and March 2023 in the Catholic University of Murcia Randomization divided the participants in two groups, depending on whether they started consuming the caramels supplemented with HT, or the group that started consuming the placebo caramels. The patients totally consumed 60 mg of HT per day distributed into 4 caramels/day with 15 mg of HT per caramel. The caramels in treatment group contained encapsulated HT in cyclodextrins, xylitol sweetened. On the other hand, the caramels in placebo group contained cyclodextrins and they were xylitol sweetened too. Patients were segregated into 2 groups: the ones who started as HT-group and the ones who started as C-group. HT-group consumed HT caramels for 28 days, while C-group consumed placebo caramels followed by a 2-week washout period. Suddenly, groups were switched for 28 days, the ones who started as HT-group became C-group and vice-versa. The patients completely performed 4 visits during the study. In every appointment, they had blood and faeces extraction with body composition measurement. In addition, a Food Frequency Questionnaire (FFQ) based on Mediterranean Diet Serving Score (MDSS) was given to the patients in order to assess diet variability during the study period.

Interventions

DIETARY_SUPPLEMENTHT treatment

Total consumption of 60 mg/day of HT

DIETARY_SUPPLEMENTPlacebo treatment

Consumption of placebo treatment of 4 caramels/day

Sponsors

Universidad Católica San Antonio de Murcia
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Caregiver)

Masking description

Nor participant and care provider knew the treatment given.

Intervention model description

28 days of treatment: one group with HT treatment and the other with placebo treatment. 2-weeks washout period. The treatment will be switched between groups for another 28 days: those who initially consumed HT will the switch to the placebo treatment, and vice versa.

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Elevated cholesterol level: \>200 mg/dL * Elevated glucose level: \>100 mg/dL

Exclusion criteria

* Not been under antihypertensive, antidiabetic and/or hypoglycaemic agents

Design outcomes

Primary

MeasureTime frameDescription
Change of cardiovascular biomarkersup to 4 monthsEvaluating the effect of HT caramels on cardiovascular biomarkers in blood samples (mg/dL)
Change of cellular phenotype of plateletsup to 2 monthsAssessing the impact of HT caramels on cellular phenotype measured with flow cytometry

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026